Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking

ACS Nano

Volumn 7, Issue 12, 2013, Pages 10452-10464

  Xue, Xue ^a,b   Hall, Matthew D ^c   Zhang, Qiang ^b   Wang, Paul C ^d   Gottesman, Michael M ^c   Liang, Xing Jie ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HOWARD UNIVERSITY   (United States)

Author keywords

abnormal membrane proteins; cancer; chemotherapy; cisplatin; drug resistance; membrane trafficking; nanoscale drug delivery platforms; nanotechnology

Indexed keywords

CANCER; CIS-PLATIN; DRUG RESISTANCE; MEMBRANE PROTEINS; MEMBRANE TRAFFICKING; NANO SCALE;

CELL MEMBRANES; CHEMOTHERAPY; DRUG DELIVERY; NANOTECHNOLOGY; PLATINUM;

PLATINUM COMPOUNDS;

ANTINEOPLASTIC AGENT; CISPLATIN; LIPOPLATIN; NANOPARTICLE; PLATINUM COMPLEX;

ANIMAL; CELL CYCLE; CELL MEMBRANE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; MALE; METABOLISM; MOUSE; NANOTECHNOLOGY; PH; PROTEIN TRANSPORT; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CISPLATIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE; NANOPARTICLES; NANOTECHNOLOGY; ORGANOPLATINUM COMPOUNDS; PROTEIN TRANSPORT;

EID: 84891353977     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn405004f     Document Type: Review

References (144)

1. McWhinney, S. R.; Goldberg, R. M.; McLeod, H. L. Platinum neurotoxicity pharmacogenetics Mol. Cancer Ther. 2009, 8, 6-10
2. Cepeda, V.; Fuertes, M. A.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J. M. Biochemical mechanisms of cisplatin cytotoxicity Anticancer Agents Med. Chem. 2007, 7, 3-18
3. Paris, I.; Cappellini, G. C.; Malaguti, P.; Bassanelli, M.; Marchetti, P. Pharmacogenomics and chemotherapy Recenti Prog. Med. 2010, 101, 277-282
4. Gottlieb, J. A.; Drewinko, B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy Cancer Chemother. Rep. 1975, 59, 621-628
5. Shen, D. W.; Pouliot, L. M.; Hall, M. D.; Gottesman, M. M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 2012, 64, 706-721
6. Hall, M. D.; Okabe, M.; Shen, D. W.; Liang, X. J.; Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535
7. Koberle, B.; Tomicic, M. T.; Usanova, S.; Kaina, B. Cisplatin resistance: preclinical findings and clinical implications Biochim. Biophys. Acta 2010, 1806, 172-182
8. Pelletier, H.; Millot, J. M.; Chauffert, B.; Manfait, M.; Genne, P.; Martin, F. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion Cancer Res. 1990, 50, 6626-6631
9. Binks, S. P.; Dobrota, M. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine Biochem. Pharmacol. 1990, 40, 1329-1336
10. Huang, Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy Cancer Metastasis Rev. 2007, 26, 183-201
11. Ohmichi, M.; Hayakawa, J.; Tasaka, K.; Kurachi, H.; Murata, Y. Mechanisms of platinum drug resistance Trends Pharmacol. Sci. 2005, 26, 113-116
12. Wernyj, R. P.; Morin, P. J. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel Drug Resist. Updates 2004, 7, 227-232
13. Koga, H.; Kotoh, S.; Nakashima, M.; Yokomizo, A.; Tanaka, M.; Naito, S. Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines Int. J. Oncol. 2000, 16, 1003-1007
14. Stordal, B.; Hamon, M.; McEneaney, V.; Roche, S.; Gillet, J. P.; O'Leary, J. J.; Gottesman, M.; Clynes, M. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein PLoS One 2012, 7, e40717
15. +-ATPase α1 subunit in the intracellular accumulation of cisplatin Cancer Chemother. Pharmacol. 2006, 57, 84-90
16. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol. Rev. 2006, 86, 849-899
17. Song, I. S.; Savaraj, N.; Siddik, Z. H.; Liu, P.; Wei, Y.; Wu, C. J.; Kuo, M. T. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells Mol. Cancer Ther. 2004, 3, 1543-1549
18. Samimi, G.; Varki, N. M.; Wilczynski, S.; Safaei, R.; Alberts, D. S.; Howell, S. B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients Clin. Cancer Res. 2003, 9, 5853-5859
19. More, S. S.; Akil, O.; Ianculescu, A. G.; Geier, E. G.; Lustig, L. R.; Giacomini, K. M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity J. Neurosci. 2010, 30, 9500-9509
20. Huang, Y.; Sadee, W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells Cancer Lett. 2006, 239, 168-182
21. Ejendal, K. F.; Hrycyna, C. A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2 Curr. Protein Pept. Sci. 2002, 3, 503-511
22. Kis, O.; Robillard, K.; Chan, G. N.; Bendayan, R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters Trends Pharmacol. Sci. 2010, 31, 22-35
23. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of ABC transporters in drug resistance, metabolism and toxicity Curr. Drug Delivery 2004, 1, 27-42
24. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
25. Fukuda, Y.; Schuetz, J. D. ABC transporters and their role in nucleoside and nucleotide drug resistance Biochem. Pharmacol. 2012, 83, 1073-1083
26. Fujino, H.; Saito, T.; Ogawa, S.; Kojima, J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase J. Pharm. Pharmacol. 2005, 57, 1305-1311
27. Marin, J. J.; Briz, O.; Monte, M. J.; Blazquez, A. G.; Macias, R. I. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs Curr. Cancer Drug Targets 2012, 12, 402-438
28. Larson, C. A.; Blair, B. G.; Safaei, R.; Howell, S. B. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs Mol. Pharmacol. 2009, 75, 324-330
29. Fink, D.; Nebel, S.; Aebi, S.; Nehme, A.; Howell, S. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin Int. J. Oncol. 1997, 11, 539-542
30. Liang, X. J.; Yin, J. J.; Zhou, J. W.; Wang, P. C.; Taylor, B.; Cardarelli, C.; Kozar, M.; Forte, R.; Aszalos, A.; Gottesman, M. M. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells Exp. Cell Res. 2004, 293, 283-291
31. Xue, X.; You, S.; Zhang, Q.; Wu, Y.; Zou, G. Z.; Wang, P. C.; Zhao, Y. L.; Xu, Y.; Jia, L.; Zhang, X. et al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction Mol. Pharmaceutics 2012, 9, 634-644
32. + channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance Anticancer Res. 2005, 25, 4113-4122
33. Todor, I. N.; Lukyanova, N. Y.; Chekhun, V. F. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells Exp. Oncol. 2012, 34, 97-100
34. Michelakis, E. D.; Webster, L.; Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer Br. J. Cancer 2008, 99, 989-994
35. Stacpoole, P. W. The pharmacology of dichloroacetate Metabolism 1989, 38, 1124-1144
36. Dhar, S.; Lippard, S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 22199-22204
37. Xiao, H.; Yan, L.; Zhang, Y.; Qi, R.; Li, W.; Wang, R.; Liu, S.; Huang, Y.; Li, Y.; Jing, X. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy Chem. Commun. 2012, 48, 10730-10732
38. Yadav, S.; van Vlerken, L. E.; Little, S. R.; Amiji, M. M. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells Cancer Chemother. Pharmacol. 2009, 63, 711-722
39. Kievit, F. M.; Wang, F. Y.; Fang, C.; Mok, H.; Wang, K.; Silber, J. R.; Ellenbogen, R. G.; Zhang, M. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro J. Controlled Release 2011, 152, 76-83
40. Huang, Z.; Huang, Y. The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells Cancer Invest. 2005, 23, 26-32
41. Murakami, T.; Shibuya, I.; Ise, T.; Chen, Z. S.; Akiyama, S.; Nakagawa, M.; Izumi, H.; Nakamura, T.; Matsuo, K.; Yamada, Y. et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance Int. J. Cancer 2001, 93, 869-874
42. Laurencot, C. M.; Kennedy, K. A. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells Oncol. Res. 1995, 7, 371-379
43. Yanishevsky, R. M.; Stein, G. H. Regulation of the cell cycle in eukaryotic cells Int. Rev. Cytol. 1981, 69, 223-259
44. Robinson, A. C.; Collins, J. F.; Donachie, W. D. Prokaryotic and eukaryotic cell-cycle proteins Nature 1987, 328, 766
45. Peeper, D. S.; van der Eb, A. J.; Zantema, A. The G1/S cell-cycle checkpoint in eukaryotic cells Biochim. Biophys. Acta 1994, 1198, 215-230
46. Lin, W.; Arthur, G. Phospholipids are synthesized in the G2/M phase of the cell cycle Int. J. Biochem. Cell Biol. 2007, 39, 597-605
47. Jackowski, S. Coordination of membrane phospholipid synthesis with the cell cycle J. Biol. Chem. 1994, 269, 3858-3867
48. Hunter, T. Regulation of the eukaryotic cell cycle. Introduction Ciba Found. Symp. 1992, 170, 1-6
49. Nigg, E. A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle Bioessays 1995, 17, 471-480
50. Hoyt, M. A. Eliminating all obstacles: regulated proteolysis in the eukaryotic cell cycle Cell 1997, 91, 149-151
51. Owa, T.; Yoshino, H.; Yoshimatsu, K.; Nagasu, T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents Curr. Med. Chem. 2001, 8, 1487-1503
52. Shen, H.; Perez, R. E.; Davaadelger, B.; Maki, C. G. Two 4N cell-cycle arrests contribute to cisplatin-resistance PLoS One 2013, 8, e59848
53. Eastman, A. The mechanism of action of cisplatin: from adducts to apoptosis. In Cisplatin: chemistry and biochemistry of a leading anticancer drug; Lippert, B., Ed.; Verlag Helvetica Chimica Acta: Switzerland, 1999; pp 111-134.
54. Shah, M. A.; Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy Clin. Cancer Res. 2001, 7, 2168-2181
55. Pouliot, L. M.; Chen, Y. C.; Bai, J.; Guha, R.; Martin, S. E.; Gottesman, M. M.; Hall, M. D. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family Cancer Res. 2012, 72, 5945-5955
56. Ling, X.; Wen, L.; Zhou, Y. Role of mitochondrial translocation of telomerase in hepatocellular carcinoma cells with multidrug resistance Int. J. Med. Sci. 2012, 9, 545-554
57. Hirai, H.; Iwasawa, Y.; Okada, M.; Arai, T.; Nishibata, T.; Kobayashi, M.; Kimura, T.; Kaneko, N.; Ohtani, J.; Yamanaka, K. et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol. Cancer Ther. 2009, 8, 2992-3000
58. Komizu, Y.; Ueoka, H.; Goto, K.; Ueoka, R. Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis Int. J. Nanomed. 2011, 6, 1913-1920
59. Yang, X. Q.; Zhang, Z. M.; Wang, D.; Wang, G.; Zeng, L. L.; Yang, Z. Z. nm23-H1-siRNA enhances the chemosensitivity to liposome-encapsulated paclitaxel in lung adenocarcinoma cells in vitro Zhonghua Zhongliu Zazhi 2011, 33, 405-409
60. Ruan, F.; Xie, X. K.; Liu, S. Y. Inhibitory effects of survivin antisense oligonucleotide on drug-resistant human ovarian cancer cell COC1/DDP Aizheng 2004, 23, 896-899
61. Roa, W.; Zhang, X.; Guo, L.; Shaw, A.; Hu, X.; Xiong, Y.; Gulavita, S.; Patel, S.; Sun, X.; Chen, J. et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle Nanotechnology 2009, 20, 375101
62. Lange, T. S.; Kim, K. K.; Singh, R. K.; Strongin, R. M.; McCourt, C. K.; Brard, L. Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells PLoS One 2008, 3, e2303
63. Eom, H. J.; Choi, J. p38 MAPK activation, DNA damage, cell cycle arrest and apoptosis as mechanisms of toxicity of silver nanoparticles in Jurkat T cells Environ. Sci. Technol. 2010, 44, 8337-8342
64. Asharani, P. V.; Sethu, S.; Lim, H. K.; Balaji, G.; Valiyaveettil, S.; Hande, M. P. Differential regulation of intracellular factors mediating cell cycle, DNA repair and inflammation following exposure to silver nanoparticles in human cells Genome Integr. 2012, 3, 2
65. Wang, C. H.; Shih, W. C.; Chang, H. C.; Kuo, Y. Y.; Hung, W. C.; Ong, T. G.; Li, W. S. Preparation and characterization of amino-linked heterocyclic carbene palladium, gold, and silver complexes and their use as anticancer agents that act by triggering apoptotic cell death J. Med. Chem. 2011, 54, 5245-5249
66. Casaluce, F.; Sgambato, A.; Maione, P.; Ciardiello, F.; Gridelli, C. Emerging mitotic inhibitors for non-small cell carcinoma Expert Opin. Emerging Drugs 2013, 18, 97-107
67. Cui, M.; Naczynski, D. J.; Zevon, M.; Griffith, C. K.; Sheihet, L.; Poventud-Fuentes, I.; Chen, S.; Roth, C. M.; Moghe, P. V. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy Adv. Healthcare Mater. 2013, 2, 1236-1245
68. Sasidharan, A.; Chandran, P.; Menon, D.; Raman, S.; Nair, S.; Koyakutty, M. Rapid dissolution of ZnO nanocrystals in acidic cancer microenvironment leading to preferential apoptosis Nanoscale 2011, 3, 3657-3669
69. Coronnello, M.; Marcon, G.; Carotti, S.; Caciagli, B.; Mini, E.; Mazzei, T.; Orioli, P.; Messori, L. Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity Oncol. Res. 2000, 12, 361-370
70. Blagosklonny, M. V.; Robey, R.; Bates, S.; Fojo, T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs J. Clin. Invest. 2000, 105, 533-539
71. Shi, J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications Nano Lett. 2010, 10, 3223-3230
72. Talevi, A.; Gantner, M. E.; Ruiz, M. E. Applications of nanosystems to anticancer drug therapy (part I. nanogels, nanospheres, nanocapsules). Recent Pat. Anticancer Drug Discovery 2012, Epub ahead of print
73. Ruiz, M. E.; Gantner, M. E.; Talevi, A. Applications of nanosystems to anticancer drug therapy (part II. dendrimers, micelles, lipid-based nanosystems). Recent Pat. Anticancer Drug Discovery 2013, Epub ahead of print
74. Jabir, N. R.; Tabrez, S.; Ashraf, G. M.; Shakil, S.; Damanhouri, G. A.; Kamal, M. A. Nanotechnology-based approaches in anticancer research Int. J. Nanomed. 2012, 7, 4391-4408
75. Goncalves, A. S.; Macedo, A. S.; Souto, E. B. Therapeutic nanosystems for oncology nanomedicine Clin. Transl. Oncol. 2012, 14, 883-890
76. Kratz, F.; Warnecke, A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems J. Controlled Release 2012, 164, 221-235
77. Cheng, J.; Meziani, M. J.; Sun, Y. P.; Cheng, S. H. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance Toxicol. Appl. Pharmacol. 2011, 250, 184-193
78. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment Urol. Oncol. 2008, 26, 57-64
79. Arayne, M. S.; Sultana, N. Review: nanoparticles in drug delivery for the treatment of cancer Pak. J. Pharm. Sci. 2006, 19, 258-268
80. Liang, X. J.; Meng, H.; Wang, Y.; He, H.; Meng, J.; Lu, J.; Wang, P. C.; Zhao, Y.; Gao, X.; Sun, B. et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 7449-7454
81. Singhal, S. S.; Yadav, S.; Singhal, J.; Sahu, M.; Sehrawat, A.; Awasthi, S. Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76 FEBS Lett. 2008, 582, 3408-3414
82. Boohaker, R. J.; Zhang, G.; Lee, M. W.; Nemec, K. N.; Santra, S.; Perez, J. M.; Khaled, A. R. Rational development of a cytotoxic peptide to trigger cell death Mol. Pharmaceutics 2012, 9, 2080-2093
83. Taratula, O.; Garbuzenko, O. B.; Chen, A. M.; Minko, T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA J. Drug Target 2011, 19, 900-914
84. Nosko, M. M.; Pivnyuk, V. M.; Solyanik, G. I.; Kulik, G. I.; Todor, I. N.; Momot, V. Y.; Melnikov, O. R.; Ponomareva, O. V.; Chekhun, V. F. Biodistribution analysis of cisplatin in liposomal form in animals with cisplatin-resistant and cisplatin-sensitive carcinoma Exp. Oncol. 2010, 32, 40-43
85. dos Santos Giuberti, C.; de Oliveira Reis, E. C.; Ribeiro Rocha, T. G.; Leite, E. A.; Lacerda, R. G.; Ramaldes, G. A.; de Oliveira, M. C. Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin J. Liposome Res. 2011, 21, 60-69
86. Zalba, S.; Garrido, M. J. Liposomes, a promising strategy for clinical application of platinum derivatives Expert Opin. Drug Delivery 2013, 10, 829-844
87. Lucas, X.; Simon, S.; Schubert, R.; Gunther, S. Discovery of the inhibitory effect of a phosphatidylinositol derivative on P-glycoprotein by virtual screening followed by in vitro cellular studies PLoS One 2013, 8, e60679
88. Yefimova, S. L.; Kurilchenko, I. Y.; Tkacheva, T. N.; Rozhkov, V. A.; Sorokin, A. V.; Lukianova, N. Y.; Bezdenezhnykh, N. A.; Malyukin, Y. V.; Chekhun, V. F. Comparative study of dye-loaded liposome accumulation in sensitive and resistant human breast cancer cells Exp. Oncol. 2012, 34, 101-106
89. Chen, M.; Chen, J.; Hou, T.; Fang, Y.; Sun, W.; Hu, R.; Cai, B. Effect of phospholipid composition on pharmaceutical properties and anti-tumor activity of stealth liposomes containing brucine Zhongguo Zhongyao Zazhi 2011, 36, 864-867
90. Krieger, M. L.; Eckstein, N.; Schneider, V.; Koch, M.; Royer, H. D.; Jaehde, U.; Bendas, G. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro Int. J. Pharm. 2010, 389, 10-17
91. Ye, S.; Yang, W.; Wang, Y.; Ou, W.; Ma, Q.; Yu, C.; Ren, J.; Zhong, G.; Shi, H.; Yuan, Z. et al. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer Int. J. Mol. Med. 2013, 31, 33-42
92. Farhat, F. S.; Temraz, S.; Kattan, J.; Ibrahim, K.; Bitar, N.; Haddad, N.; Jalloul, R.; Hatoum, H. A.; Nsouli, G.; Shamseddine, A. I. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer Clin. Breast Cancer 2011, 11, 384-389
93. Canta, A.; Chiorazzi, A.; Carozzi, V.; Meregalli, C.; Oggioni, N.; Sala, B.; Crippa, L.; Avezza, F.; Forestieri, D.; Rotella, G. et al. In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin) Cancer Chemother. Pharmacol. 2011, 68, 1001-1008
94. Devarajan, P.; Tarabishi, R.; Mishra, J.; Ma, Q.; Kourvetaris, A.; Vougiouka, M.; Boulikas, T. Low renal toxicity of lipoplatin compared to cisplatin in animals Anticancer Res. 2004, 24, 2193-2200
95. Arienti, C.; Tesei, A.; Ravaioli, A.; Ratta, M.; Carloni, S.; Mangianti, S.; Ulivi, P.; Nicoletti, S.; Amadori, D.; Zoli, W. Activity of lipoplatin in tumor and in normal cells in vitro Anticancer Drugs 2008, 19, 983-990
96. Chen, C. J.; Chin, J. E.; Ueda, K.; Clark, D. P.; Pastan, I.; Gottesman, M. M.; Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 1986, 47, 381-389
97. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7735-7738
98. Batrakova, E. V.; Li, S.; Vinogradov, S. V.; Alakhov, V. Y.; Miller, D. W.; Kabanov, A. V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization J. Pharmacol. Exp. Ther. 2001, 299, 483-493
99. Batrakova, E. V.; Li, S.; Li, Y.; Alakhov, V. Y.; Kabanov, A. V. Effect of pluronic P85 on ATPase activity of drug efflux transporters Pharm. Res. 2004, 21, 2226-2233
100. Wu, Y. C.; Ling, T. Y.; Lu, S. H.; Kuo, H. C.; Ho, H. N.; Yeh, S. D.; Shen, C. N.; Huang, Y. H. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4 Cancer Res. 2012, 72, 4963-4973
101. Garg, A.; Tisdale, A. W.; Haidari, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide Int. J. Pharm. 2009, 366, 201-210
102. Codogno, P.; Meijer, A. J. Autophagy and signaling: their role in cell survival and cell death Cell Death Differ. 2005, 12 (Suppl 2) 1509-1518
103. Levine, B.; Yuan, J. Autophagy in cell death: an innocent convict? J. Clin. Invest. 2005, 115, 2679-2688
104. Ren, J. H.; He, W. S.; Nong, L.; Zhu, Q. Y.; Hu, K.; Zhang, R. G.; Huang, L. L.; Zhu, F.; Wu, G. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy Cancer Biother. Radiopharm. 2010, 25, 75-80
105. Sirichanchuen, B.; Pengsuparp, T.; Chanvorachote, P. Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells Mol. Cell. Biochem. 2012, 364, 11-18
106. Chen, S.; Rehman, S. K.; Zhang, W.; Wen, A.; Yao, L.; Zhang, J. Autophagy is a therapeutic target in anticancer drug resistance Biochim. Biophys. Acta 2010, 1806, 220-229
107. Bednarski, P. J.; Korpis, K.; Westendorf, A. F.; Perfahl, S.; Grunert, R. Effects of light-activated diazido-PtIV complexes on cancer cells in vitro Philos. Trans. R. Soc., A 2013, 371, 20120118
108. Zhang, Q.; Yang, W.; Man, N.; Zheng, F.; Shen, Y.; Sun, K.; Li, Y.; Wen, L. P. Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal Autophagy 2009, 5, 1107-1117
109. Wei, P.; Zhang, L.; Lu, Y.; Man, N.; Wen, L. C60(Nd) nanoparticles enhance chemotherapeutic susceptibility of cancer cells by modulation of autophagy Nanotechnology 2010, 21, 495101
110. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 17356-17361
111. Dhar, S.; Kolishetti, N.; Lippard, S. J.; Farokhzad, O. C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 1850-1855
112. Wilson, J. J.; Lippard, S. J. Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes Inorg. Chem. 2011, 50, 3103-31015
113. Wilson, J. J.; Lippard, S. J. Modulation of ligand fluorescence by the Pt(II)/Pt(IV) redox couple Inorg. Chim. Acta 2012, 389, 77-84
114. Dhar, S.; Liu, Z.; Thomale, J.; Dai, H.; Lippard, S. J. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device J. Am. Chem. Soc. 2008, 130, 11467-11476
115. Dhar, S.; Daniel, W. L.; Giljohann, D. A.; Mirkin, C. A.; Lippard, S. J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads J. Am. Chem. Soc. 2009, 131, 14652-14653
116. 3 Integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug ACS Nano 2012, 6, 4530-4539
117. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature Bioconjugate Chem. 2008, 19, 39-49
118. Yang, J.; Sun, X.; Mao, W.; Sui, M.; Tang, J.; Shen, Y. Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy Mol. Pharmaceutics 2012, 9, 2793-2800
119. Yang, J.; Liu, W.; Sui, M.; Tang, J.; Shen, Y. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery Biomaterials 2011, 32, 9136-9143
120. Wang, R.; Hu, X.; Wu, S.; Xiao, H.; Cai, H.; Xie, Z.; Huang, Y.; Jing, X. Biological characterization of folate-decorated biodegradable polymer-platinum(II) complex micelles Mol. Pharmaceutics 2012, 9, 3200-3208
121. Comenge, J.; Sotelo, C.; Romero, F.; Gallego, O.; Barnadas, A.; Parada, T. G.; Dominguez, F.; Puntes, V. F. Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin PLoS One 2012, 7, e47562
122. Ajima, K.; Murakami, T.; Mizoguchi, Y.; Tsuchida, K.; Ichihashi, T.; Iijima, S.; Yudasaka, M. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns ACS Nano 2008, 2, 2057-2064
123. Johnstone, T. C.; Lippard, S. J. The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs Inorg. Chem. 2013, 52, 9915-9920
124. Lian, H. Y.; Hu, M.; Liu, C. H.; Yamauchi, Y.; Wu, K. C. Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery Chem. Commun. 2012, 48, 5151-5153
125. Tao, Z.; Toms, B.; Goodisman, J.; Asefa, T. Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs ACS Nano 2010, 4, 789-794
126. Morelli, C.; Maris, P.; Sisci, D.; Perrotta, E.; Brunelli, E.; Perrotta, I.; Panno, M. L.; Tagarelli, A.; Versace, C.; Casula, M. F. et al. PEGlated mesoporous silica nanoparticles exclusively target cancer cells Nanoscale 2011, 3, 3198-3207
127. Jadhav, V. B.; Jun, Y. J.; Song, J. H.; Park, M. K.; Oh, J. H.; Chae, S. W.; Kim, I. S.; Choi, S. J.; Lee, H. J.; Sohn, Y. S. A novel micelle-encapsulated platinum(II) anticancer agent J. Controlled Release 2010, 147, 144-150
128. Shoae-Hassani, A.; Mortazavi-Tabatabaei, S. A.; Sharif, S.; Madadi, S.; Rezaei-Khaligh, H.; Verdi, J. Recombinant lambda bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line Arch. Immunol. Ther. Exp. 2013, 61, 75-83
129. Tijink, B. M.; Laeremans, T.; Budde, M.; Stigter-van Walsum, M.; Dreier, T.; de Haard, H. J.; Leemans, C. R.; van Dongen, G. A. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther. 2008, 7, 2288-2297
130. Oliveira, S.; Heukers, R.; Sornkom, J.; Kok, R. J.; van Bergen En Henegouwen, P. M. Targeting tumors with nanobodies for cancer imaging and therapy J. Controlled Release 2013, 172, 607-617
131. Chudecka-Glaz, A.; Rzepka-Gorska, I. Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors Contemp. Hematol./Oncol. 2012, 16, 520-525
132. Bourzac, K. Nanotechnology: carrying drugs Nature 2012, 491, 58-60
133. Endo, K.; Ueno, T.; Kondo, S.; Wakisaka, N.; Murono, S.; Ito, M.; Kataoka, K.; Kato, Y.; Yoshizaki, T. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma Cancer Sci. 2013, 104, 369-374
134. Baba, M.; Matsumoto, Y.; Kashio, A.; Cabral, H.; Nishiyama, N.; Kataoka, K.; Yamasoba, T. Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs J. Controlled Release 2012, 157, 112-117
135. Uchino, H.; Matsumura, Y.; Negishi, T.; Koizumi, F.; Hayashi, T.; Honda, T.; Nishiyama, N.; Kataoka, K.; Naito, S.; Kakizoe, T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 2005, 93, 678-687
136. Takahashi, R.; Ishiwatari, T. Preparation of helical gold nanowires on surfactant tubules Chem. Commun. 2004, 1406140-1406147
137. Nishiyama, N.; Kataoka, K. [Development of polymeric micelles for the delivery of antitumor agents] Gan To Kagaku Ryoho 2009, 36, 357-361
138. Murakami, M.; Cabral, H.; Matsumoto, Y.; Wu, S.; Kano, M. R.; Yamori, T.; Nishiyama, N.; Kataoka, K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting Sci. Transl. Med. 2011, 3, 64ra2
139. Huo, S.; Ma, H.; Huang, K.; Liu, J.; Wei, T.; Jin, S.; Zhang, J.; He, S.; Liang, X. J. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors Cancer Res. 2013, 73, 319-330
140. Zhao, Y.; Zhang, X.; Xue, X.; Li, Z.; Chen, F.; Li, S.; Kumar, A.; Zou, G.; Liang, X. J. High throughput detection of human neutrophil peptides from serum, saliva, and tear by anthrax lethal factor-modified nanoparticles ACS Appl. Mater. Interfaces 2013, 5, 8267-8272
141. Xue, X.; Zhao, Y.; Dai, L.; Zhang, X.; Hao, X.; Zhang, C.; Huo, S.; Liu, J.; Liu, C.; Kumar, A. et al. Spatiotemporal drug release visualized through a drug delivery system with tunable aggregation-induced emission Adv. Mater. 2013, 10.1002/adma.201302365
142. Boulikas, T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin Expert Opin. Invest. Drugs 2009, 18, 1197-1218
143. Stathopoulos, G. P.; Boulikas, T. Lipoplatin formulation review article J. Drug Delivery 2012, 2012, 581363
144. Boulikas, T.; Pantos, A.; Bellis, E.; Christofis, P. Designing platinum compounds in cancer: structures and mechanisms Cancer Ther. 2007, 5, 537-583